Epigenetics and Drug Resistance in Cancer
Author Information
Author(s): Glasspool R M, Teodoridis J M, Brown R
Primary Institution: Centre for Oncology and Applied Pharmacology, Glasgow University
Hypothesis
Clinical drug resistance may be due to changes in expression of multiple genes affected by epigenetic regulation.
Conclusion
Epigenetic changes, particularly DNA methylation, play a significant role in the development of drug resistance in cancer.
Supporting Evidence
- Epigenetic changes can lead to drug resistance in cancer cells.
- DNA methylation is a common mechanism of gene inactivation in tumors.
- Multiple genes can be affected simultaneously by epigenetic regulation.
Takeaway
Sometimes, cancer cells can change how they work without changing their DNA, which helps them resist treatment. This study looks at how these changes happen.
Methodology
The study reviews existing literature on the role of epigenetic changes in drug resistance, focusing on DNA methylation patterns.
Potential Biases
Potential biases in the interpretation of existing studies and the complexity of cancer biology may affect conclusions.
Limitations
The review is based on existing studies, which may have variability in quality and design.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website